The invention relates to novel heteroaryl compounds of Formula (I) and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.
The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.
PCSK9 INHIBITORS AND METHODS OF USE THEREOF
申请人:AstraZeneca AB
公开号:US20220220122A1
公开(公告)日:2022-07-14
The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.
[EN] PCSK9 INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PCSK9 ET LEURS PROCÉDÉS D'UTILISATION
申请人:DOGMA THERAPEUTICS INC
公开号:WO2020150473A2
公开(公告)日:2020-07-23
The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.